Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Selecta Biosciences (SELB)
NASDAQ:SELB
Holding SELB?
Track your performance easily
SELB Stock Chart & Stats
Day’s Range$0.81 - $0.94
52-Week Range― - ―
Previous Close$0.96
Volume2.77M
Average Volume (3M)N/A
Market Cap
$148.65M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Mar 14, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.00Price Target Upside240.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Selecta Biosciences News
PremiumPre-Earnings
Is SELB a Buy, Before Earnings?
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
13.04% Other Institutional Investors
86.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SELB FAQ
What was Selecta Biosciences’s price range in the past 12 months?
Currently, no data Available
What is Selecta Biosciences’s market cap?
Currently, no data Available
When is Selecta Biosciences’s upcoming earnings report date?
Selecta Biosciences’s upcoming earnings report date is Mar 14, 2024 which is 251 days ago.
How were Selecta Biosciences’s earnings last quarter?
Selecta Biosciences released its earnings results on Nov 09, 2023. The company reported -$0.058 earnings per share for the quarter, beating the consensus estimate of -$0.072 by $0.014.
Is Selecta Biosciences overvalued?
According to Wall Street analysts Selecta Biosciences’s price is currently Undervalued.
Does Selecta Biosciences pay dividends?
Selecta Biosciences does not currently pay dividends.
What is Selecta Biosciences’s EPS estimate?
Selecta Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Selecta Biosciences have?
Currently, no data Available
What happened to Selecta Biosciences’s price movement after its last earnings report?
Selecta Biosciences reported an EPS of -$0.058 in its last earnings report, beating expectations of -$0.072. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Selecta Biosciences?
Among the largest hedge funds holding Selecta Biosciences’s share is Delphi Financial Group, Inc.. It holds Selecta Biosciences’s shares valued at 740K.
---
Selecta Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (240.44% Upside)
$3.00 (240.44% Upside)
Blogger Sentiment
Bullish
SELB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 24.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Selecta Biosciences
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
---
SELB Stock 12 Month Forecast
Average Price Target
$3.00
▲(240.44% Upside)
Technical Analysis
Best Analysts Covering SELB
1 Year
1 Year Success Rate
9/30 ratings generated profit
1 Year Average Return
-16.67%
reiterated a buy rating 2 years ago
Copying John Newman's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -16.67% per trade.
---